EL7.AI
StocksMedium•19 November 2026•
3 min read

Marker Therapeutics Receives $16,206,787 Grant for MT-601 Trial

Key Facts

1CPRIT recorded a grant of $16,206,787 to support the MT-601 trial; the amount is pending contract negotiation.
2The grant was recorded on November 18, 2026, under number DP270300.
324 patients had received the treatment across 7 U.S. clinical sites as of the August 2025 update.
4MRKR shares closed at $0.8532 on November 18, 2026.

The Cancer Prevention and Research Institute of Texas awarded Marker Therapeutics $16,206,787 to support a Phase 2 trial of MT-601, according to the official grant record, which dates the award to November 18, 2026. The funding is for a study of the treatment in patients with relapsed or refractory large B-cell lymphoma after CAR-T treatment. However, the record describes the amount as “pending contract negotiation,” meaning the recorded value remains contingent on completing negotiations. The grant is numbered DP270300 and falls under the Product Development Research Program. The funding thus directly supports testing a treatment in patients who did not respond to prior therapy or relapsed after it.

The APOLLO program is testing MT-601 in patients with relapsed or refractory lymphoma for whom anti-CD19 CAR-T treatment failed or was not suitable, according to the company’s description of the study. The company says the trial is multicenter and open-label, and focuses on safety, optimal dosage and preliminary efficacy. The treatment targets six tumor antigens whose levels are elevated in lymphoma cells, according to the company. CPRIT describes the treatment cells as being derived from the patient, while the company says MT-601 uses genetically unmodified T cells. The patient group targeted in this study differs from patients who can continue CAR-T treatment, focusing on those who relapsed after it or for whom it was not an appropriate option.

In an update issued in August 2025, Marker said 24 patients with B-cell lymphoma had received MT-601 across 7 clinical sites in the United States; participants included patients with non-Hodgkin and Hodgkin lymphoma. The company said responses lasted between 3 and 24 months. Responses continued for at least 6 months in 5 patients, including 3 patients whose responses lasted at least 12 months. These figures remain background from a Phase 1 update and do not represent results from the Phase 2 trial supported by the new grant. CPRIT’s funding is therefore tied to moving toward broader testing of the treatment in the defined group of patients with large B-cell lymphoma after CAR-T.

The company said in a later update that APOLLO had moved to the dose-expansion cohort in patients with relapsed diffuse large B-cell lymphoma, evaluating the treatment at the prespecified higher dose of 400 million cells. In its earlier statement on Phase 1, Marker expected to provide another data update in the first half of 2026. That was a previous expectation, and the statement did not give a more recent date for a data update. In the context of its cancer research funding, the company previously announced in December 2024 that it had received a $9.5 million CPRIT grant to study MT-601 in patients with metastatic pancreatic cancer. The current award is part of the institute board’s approval on November 18 of 76 grants totaling more than $148 million for research, product development, early detection and prevention.

Alongside the grant announcement, Marker Therapeutics shares, trading under the ticker MRKR, closed at $0.8532 in the November 18, 2026 session, according to EL7 daily data. The event combines funding dedicated to developing MT-601 with a prior record of early results the company reported, including responses in some participants. But the grant amount recorded remains subject to contract negotiations, and the response data cited date to the 2025 Phase 1 update. The company’s earlier statement on the data gave no subsequent date later than its expectation for the first half of 2026.

Open on chart